Walking Fish Therapeutics Launches With $50 Million In Series A Financing To Accelerate Development Of B Cell Therapies For Multiple Diseases

Sep 13, 2021•almost 4 years ago

Amount Raised

$50 Million

Round Type

series a

San FranciscoBiotechnologyScience And EngineeringHealth Care

Description

Walking Fish Therapeutics, a leader in B cell engineering, today announced the close of $50M Series A financing— led by investors including Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.

Company Information

Company

Walking Fish Therapeutics

Location

San Francisco, California, United States

About

A leader in B cell medicines, Walking Fish Therapeutics has made critical advances in engineering technologies to rapidly advance cell-based therapeutics to treat serious diseases, concentrating on oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production. For more information and important updates, please visit https://www.walkingfishtx.com/

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Walking Fish Therapeutics Launches With $50 Million In Series A Financing To Accelerate Development Of B Cell Therapies For Multiple Diseases

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information